

Dr Rejman CA-OPU2

From: David Pink HCD-PH1(A)

Date: 16 July 1996

cc: Dr Mann
Dr Rotblatt
Dr Purves
Mr Paley
Mr Pudlo
Mr Spellman
Mr Pugh

CO 871

**GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND
OTHER HEREDITARY COAGULATION DISORDERS**

1. Thank you for your note of 11 July to Tom Mann and the opportunity to consider the attached papers from Dr B T Colvin.
2. Sadly I cannot be very enthusiastic about their potential to be clinical guidelines. Firstly, these are not about the management of patients with Haemophilia and related disorders but rather guidance about prescribing options. Despite the helpful classification of evidence categories, the 'guidance' is not robustly evidence-based. The papers show no evidence of support from the relevant professional body (Royal College of Physicians?) nor do they indicate the involvement of purchasers of healthcare or patients in their production or consideration.
3. I understand that we sent you copies of guidelines' standards last year. I feel it would be unwise to put these guidelines through the rigours of meeting COG standards, which they have to do to compete for a place in the nationally commended clinical guidelines framework. However, I would be happy to advise you further if you and policy colleagues feel there are other ways in which this work could be utilised.

GRO-C

David Pink
HCD-PH1(A)
Room 3W42
Ext. GRO-C